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Identifying candidates that rejuvenate aged muscle stem cells is an important strategy toward developing
therapies to treat age-related diseases. In this issue, Egerman et al. (2015) re-investigate the activity of
GDF11 in myogenesis, recently suggested as an anti-aging agent, and instead find a potent inhibitory effect
on skeletal muscle regeneration.The mythical fountain of youth has a long
history in human imagination, stretching
back at least 2,000 years to the writings
of Herodotus. In 2005, a seminal manu-
script from the laboratory of Tom Rando
described an experiment whereby the
joining of the circulation of older and
younger mice via heterochronic parabi-
otic pairing resulted in the rejuvenation
of stem cells in the older animal (Conboy
et al., 2005). The search for the humoral
factors affecting the function of aging
stem cells was on.
Proteomics analysis comparing young
and aged serum using SOMAmer tech-
nology suggested the TGF-b superfamily
member GDF11 as a candidate, since
their analysis indicated reduced levels
in older mice and presented data that
suggested GDF11 was capable of
reversing age-related hypertrophy (Lof-
fredo et al., 2013). The authors then
reported that systemic injection of
GDF11 reverses age-related dysfunction
in skeletal muscle (Sinha et al., 2014) as
well as vascular and neurogenic function
in the brain (Katsimpardi et al., 2014).
These findings were surprising because
a closely related TGF-b member, myo-
statin, is a potent inhibitor of skeletal
muscle growth (McPherron et al., 1997).
Moreover, mice carrying targeted muta-
tions in Gasp-1 and/or Gasp-2, two
specific inhibitors of myostatin and
GDF11, exhibit impaired muscle regene-
rative capacity consistent with an upre-
gulation of myostatin and GDF11
signaling (Lee and Lee, 2013). Thus,
the mechanism by which GDF11 could
improve muscle regeneration and reju-
venate aged satellite cells was not at
all clear.54 Cell Metabolism 22, July 7, 2015 ª2015 EIn this issue of Cell Metabolism,
Egerman et al. (2015) undertook a careful
analysis of the function of GDF11 in
young and aged mice. They report the
opposite of what Sinha et al. reported,
that overexpression of GDF11 results
in impaired satellite cell function and
reduced muscle regeneration. Notably,
systemic delivery of GDF11 into old mice
had no effect, whereas in young mice
muscle regeneration was delayed due to
reduced expansion and differentiation of
satellite cells.
Myostatin andGDF11 are highly homol-
ogous and exhibit 89% identity in amino
acid sequence in the mature protein.
Egerman and co-workers first assessed
the specificity of SOMAmer analysis
to identify GDF11. They found that the
SOMAmer analysis used in the prior
papers (Loffredo et al., 2013; Sinha
et al., 2014) was unable to discriminate
between myostatin and GDF11. Similarly,
they showed by western blot analysis
that the GDF11 antibody previously used
by Loffredo et al. (2013) detects both
myostatin and GDF11. Notably, this
antibody also showed that the combined
GDF11/myostatin seems to increase
with age, not decrease as previously
reported, if the entirety of the signal was
accounted for.
To specifically detect GDF11 levels in
serum, Egerman et al. established an
immunoassay specific for GDF11 protein.
As GDF11 levels in mice were below the
detection sensitivity for this immuno-
assay, the authors measured GDF11
concentration in both young and aged
rats and humans and demonstrated
that GDF11 actually increases during
aging. This was further confirmedlsevier Inc.by RNA-sequencing analysis on rat
skeletal muscles from 6 to 24 months of
age. Interestingly, while GDF11 mRNA
levels increase as a function of age, myo-
statin mRNA levels undergo a decrease
(Figure 1A).
Of particular interest, myostatin and
GDF11 share the same receptor and
canonical signaling pathway (Trendelen-
burg et al., 2009). To determine whether
GDF11 could have distinct effects on
skeletal muscle cells in comparison to
myostatin, Egerman et al. treated human
primary myoblasts with different doses
of GDF11 and myostatin recombinant
proteins to decipher their signaling and
cellular effects. Importantly, Egerman
et al. found that both proteins equiva-
lently activate the canonical SMAD2/3
pathway as well as the myostatin non-
canonical MAPK pathways, and similarly
inhibit myoblast differentiation (Fig-
ure 1B). Microarray analysis did not
reveal any significant differences be-
tween GDF11- and myostatin-treated
myoblasts, supporting the notion that
GDF11 does not have a specific function
on skeletal muscle cells compared
to myostatin. Altogether, these results
suggest that GDF11 and myostatin
share the same activity on skeletal
muscle.
As Sinha et al. reported an improve-
ment of the regenerative ability in aged
mice following GDF11 systemic delivery,
Egerman et al. sought to re-analyze
the function of GDF11 on satellite cell
and muscle repair. Daily intraperitoneal
injections of GDF11 recombinant protein
(rGDF11, 0.1 mg/kg) were performed
on 1-year-old mice prior to the cardio-
toxin (CTX)-induced muscle injury, as
Figure 1. GDF11 and Myostatin Expression from Adulthood to Aging and Their Signaling
Pathways
(A) While myostatin expression decreases from 6 to 24 months in skeletal muscle rat, GDF11 expression
increases during this period.
(B) Both GDF11 andmyostatin bind to the type I and type II receptors, ACTRIIB and ALK-4/5, respectively,
to activate both canonical SMAD2/3 and non-canonical MAPK (p38, JNK, ERK1/2) pathways. The myo-
statin/GDF11 signaling pathways negatively regulate skeletal muscle proliferation and differentiation
and protein synthesis, which ultimately results in muscle atrophy in adulthood.
ACTRIIB, activin receptor type-IIB; AKT, protein kinase B; ALK4/5, activin-like kinase 4/5; eIF, translation
initiation factor; ERK1/2, extracellular signal-regulated kinase 1/2; FOXO, forkhead box protein O; GSK3-
b, glycogen synthase kinase 3 b; JNK, c-Jun N-terminal kinase; LC3, microtubule-associated protein 1A/
1B-light chain 3; MAFbx, muscle atrophy F-box; MAPK, mitogen-activated protein kinase; mTORC1,
mammalian target of rapamycin complex 1; MuRF1, muscle RING-finger protein 1; p70S6K, p70S6 ki-
nase; 4EB-P1, 4E binding protein 1.
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7 days post-CTX injection, Egerman
et al. did not observe any difference in
the regenerative capacity of aged skeletal
muscle treated with GDF11 or any change
in the number of satellite cells.
Interestingly, the administration of a
3-fold-higher dose of GDF11 also failed
to improve the regenerative capacity of
young skeletal muscle. Worse still,
GDF11 delivery dramatically decreases
the area of regenerating fibers at 14 days
post-CTX injection, suggesting impaireddifferentiation. The decreased number
of myogenin-expressing progenitors on
single myofibers treated with GDF11
for 3 days further confirmed that
GDF11 delays satellite cell progression
and differentiation. Finally, freshly iso-
lated satellite cells from adult and aged
mice cultured and treated with GDF11
exhibit a slower rate of proliferation
without any significant change in
myogenic marker expression, supporting
the notion that GDF11 limits satellite cell
expansion.Cell MetabolThe study of Egerman et al. clearly
demonstrates that GDF11 serum levels
do not decrease and instead increase
during aging; consistent with an increase,
their group previously demonstrated that
downstream SMAD signaling increases
with age (Trendelenburg et al., 2009).
They show that systemic injection of
GDF11 impairs satellite cell expansion
and differentiation, leading to decreased
regenerative capacity. This work is
entirely consistent with previous studies
that identify inhibitory functions of
GDF11 on myogenesis and muscle
regeneration (Gamer et al., 2001; Lee
and Lee, 2013; Souza et al., 2008).
Egerman et al. also demonstrate that
GDF11 and myostatin share the same
signaling pathways in skeletal muscle
cells. This study also underscores the
importance of developing therapeutic
strategies using inhibitors of GDF11/
myostatin signaling to prevent skeletal
muscle atrophy and weakness in age-
related diseases such as sarcopenia
(Lach-Trifilieff et al., 2014).
Clearly, like the mythical fountain of
youth, GDF11 is not the long-sought
rejuvenation factor. Given the findings
of Egerman et al. and the clinical impor-
tance of therapeutic strategies involv-
ing the inhibition of GDF11/myostatin,
the suggested ‘‘rejuvenating’’ activity of
GDF11 in the heart and brain (Katsim-
pardi et al., 2014; Loffredo et al., 2013)
should also be re-examined, since the
underlying premise of those other two
manuscripts, that GDF11 decreases
with age, is contradicted by the Egerman
manuscript.REFERENCES
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Emergent research in the past decades has brought to light the importance of lymphatic vessels in tissue
homeostasis, immunity, metabolism, and inflammation. InNature, Klotz et al. (2015) demonstrate that cardiac
lymphatics have a unique ontology compared to visceral lymphatics and that promoting their growth can
improve cardiac function following injury.Studies in the 18th and 20th centuries
established the existence of an extensive
lymphatic network in the mammalian
heart and charted its anatomy and
drainage pathways (Miller, 2011). Despite
this knowledge, together with the fact
that interference with lymphatic drainage
predisposes to the development of
edema, infection, inflammation, and
tissue fibrosis, the ontogeny and func-
tions of cardiac lymphatic vessels in
(patho)physiologic processes have been
neglected.
In a recent study, Klotz and colleagues
evaluated the embryonic origin of cardiac
lymphatic vessels. Whether or not more
than one source of lymphatic endothelial
progenitor cells exists in the embryo has
been a long-debated topic. In re-visiting
this question, several recent publications,
including that of Klotz and colleagues,
have identified sources of progenitor cells
in addition to the venous-derived pool
that contribute to generation of lymphatic
vasculature in a tissue-specific manner
(Klotz et al., 2015; Martinez-Corral et al.,
2015; Stanczuk et al., 2015). Klotz et al.
mapped the development of cardiac
lymphatic vessels from mid-embryo-
genesis (E12.5) to P15, noting that the
first obvious lymphatic endothelial cellsdid not sprout from pre-existing coronary
vessels, but migrated in from extra-car-
diac sources (Figure 1). Lineage tracing
studies using Tie2Cre and PdgfbCreERT2
mouse lines, both of which label endo-
thelial cells, showed that up to 20%
of cardiac lymphatic endothelial cells
derive from non-endothelial progenitor
cell sources. Lineage tracing using
markers of established sources of
cardiac progenitor cells—the pro-epicar-
dial organ (Wt1CreERT2), cardiac meso-
derm (Mesp1Cre, Nkx2-5Cre), or cardiac
neural crest (Wnt1Cre)—demonstrated
that none of these lineages were found
to generate lymphatic vascular endothe-
lial cell progeny.
Hemogenic endothelium refers to a
specialized population of endothelial cells
giving rise to hemopoietic stem/progeni-
tor cells. To investigate whether cardiac
lymphatic endothelial cells derive from
hemogenic endothelium during embryo-
genesis, lineage tracing using Vav1Cre,
PdgfrbCre, and Csf1rCreERT2 lines was
undertaken and documented a contribu-
tion to the generation of cardiac lymphatic
vessels, though with various degrees of
magnitude; PdgfrbCre labeled cardiac
lymphatic endothelial cells with highest
efficiency (28% at E17.5), followedby Vav1Cre (14%) and Csf1rCreERT2
(< 5%). Possible reasons underlying vari-
ations in labeling include the inducible
nature of the Csf1rCreERT2 line (induced
with one pulse of 4-hydroxytamoxifen
at E7.5), compared to constitutive
PdgfrbCre and Vav1Cre lines, and the
degree of restriction of expression of
each of these genes in hemogenic versus
other endothelial/hemopoietic compart-
ments. Nonetheless, studies in which
Prox1 was deleted in Tie2+ and Vav1+
compartments provided additional evi-
dence for a dual endothelial and hemo-
genic endothelial progenitor cell origin of
cardiac lymphatic vessels (Figure 1).
Deletion of Prox1 using Tie2Cre resulted
in virtual absence of cardiac lymphatic
vessels during embryogenesis, coupled
with dysmorphic hearts. Whether defec-
tive heart morphology was a result of the
absence of lymphatic vessels, or due to
a role for Prox1 in endocardial cells was
not conclusively established, though
formation of the ventricular septa and
cardiac valves appeared normal in mutant
mice. Various degrees of severity of
disruption to the cardiac lymphatic
vessels were observed in embryonic
Tie2CreProx1flox/flox mice, and an essen-
tially normal coverage of lymphatic
